Genetic testing could spur Erbitux drug sales

Back to TopCommentsE-mailPrintBookmark and Share

Genetic screening to predict which bowel cancer patients will benefit from Eli Lilly and Co.'s tumor- fighting drug Erbitux is becoming more common, according to the Indianapolis-based company's overseas partner, Merck KGaA, while citing a survey that may point to broader use of the treatment.

At least 42 percent of metastatic colorectal cancer patients had been tested early last year for a gene that can predict whether Erbitux will help them, said Oliver Kisker, Merck’s head of cancer clinical development. Testing rates reached 60 percent by the end of 2009, Kisker told German magazine Wirtschaftswoche this month. Screening rates rose further this year, he said Monday, while declining to confirm the Wirtschaftswoche report.

Merck is counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer after European regulators refused to widen approval of the drug to lung cancer patients last year. Research has shown the medicine is more likely to be effective in colorectal cancer patients without a mutated version of the gene. Use of the test spread from 2.5 percent of patients in 2008, the Merck survey found.

“This is amazing,” Kisker said in a telephone interview. The increase is “a very important indicator to us that this treatment now becomes, at least for many areas, part of the standard treatment.”

The survey results through early last year will be presented Tuesday at the American Society of Clinical Oncology meeting in Chicago. Results through early 2010 will be presented at the World Congress on Gastrointestinal Cancer in June, Kisker said.

Erbitux competes with Roche Holding AG’s Avastin and with Amgen Inc.’s Vectibix. Of the 42 percent of patients tested for K-ras in early 2009, 44 percent were treated with the Lilly drug, according to the survey. Almost a quarter of physicians use the genetic screening as a standard part of the diagnostic procedure for metastatic colorectal cancer, Merck said.

The company surveyed 1,254 physicians in Asia, Europe and Latin America. Merck, which isn’t related to U.S. drugmaker Merck & Co., sells Erbitux outside the U.S. and Canada. Lilly and Bristol-Myers Squibb Co. market the medicine in the U.S.

Merck reported $856 million in Erbitux sales last year. The drugmaker’s oncology program suffered twin setbacks in the past 12 months, as European regulators rejected Erbitux in lung cancer and U.S. regulators placed trials of its therapeutic cancer vaccine Stimuvax on hold in March after a patient developed a brain infection while taking it.

Merck remains in talks with the Food and Drug Administration about the halted Stimuvax trials, Kisker said. He declined to say when the discussions would finish or what kind of information the regulator requested.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. I always giggle when I read comments from people complaining that a market is "too saturated" with one thing or another. What does that even mean? If someone is able to open and sustain a new business, whether you think there is room enough for them or not, more power to them. Personally, I love visiting as many of the new local breweries as possible. You do realize that most of these establishments include a dining component and therefore are pretty similar to restaurants, right? When was the last time I heard someone say "You know, I think we have too many locally owned restaurants"? Um, never...

  2. It's good to hear that the festival is continuing to move forward beyond some of the narrow views that seemed to characterize the festival and that I and others had to deal with during our time there.

  3. Corner Bakery announced in March that it had signed agreements to open its first restaurants in Indianapolis by the end of the year. I have not heard anything since but will do some checking.

  4. "The project still is awaiting approval of a waiver filed with the Federal Aviation Administration that would authorize the use of the land for revenue-producing and non-aeronautical purposes." I wonder if the airport will still try to keep from paying taxes on these land tracts, even though they are designated as "non aeronatical?"

  5. How is this frivolous? All they are asking for is medical screenings to test the effects of their exposure. Sounds like the most reasonable lawsuit I've read about in a while. "may not have commited it" which is probably why they're suing to find out the truth. Otherwise they could just ask Walmart, were you negligent? No? OK, thanks for being honest.